Elizabeth Ramsey, DO
Psychiatry · Meadville, PANPI 1710290010
Payments from drug & device makers
Across 668 payments — averaging $16.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$3K
- Alkermes, Inc.$1K
- Neurocrine Biosciences, Inc.$782
- Otsuka America Pharmaceutical, Inc.$689
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$618
- AbbVie$601
- plus $4K from 25 others
What the payments were for
- Food & beverage$10,32597%
- Education$3633%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 200 | $2,586 |
| Alkermes, Inc. | 67 | $1,107 |
| Neurocrine Biosciences, Inc. | 41 | $782 |
| Otsuka America Pharmaceutical, Inc. | 36 | $689 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 29 | $618 |
| AbbVie | 36 | $601 |
| Johnson & Johnson | 29 | $543 |
| Merck | 32 | $535 |
| Lundbeck LLC | 27 | $449 |
| Axsome Therapeutics, Inc. | 26 | $431 |
| Takeda Pharmaceuticals U.S.A., Inc. | 35 | $395 |
| Vanda Pharmaceuticals Inc. | 18 | $383 |
| E.r. Squibb & Sons, L.L.C. | 19 | $315 |
| Corium, LLC | 16 | $270 |
| Ironshore Pharmaceuticals Inc. | 7 | $147 |
| Eisai Inc. | 8 | $120 |
| Sunovion Pharmaceuticals Inc. | 10 | $113 |
| Indivior Inc. | 6 | $108 |
| Novo Nordisk | 6 | $102 |
| Sage Therapeutics, LLC | 4 | $96 |
| Idorsia Pharmaceuticals US Inc | 3 | $44 |
| Avanir Pharmaceuticals, Inc. | 2 | $44 |
| Supernus Pharmaceuticals, Inc. | 2 | $41 |
| Collegium Pharmaceutical, Inc. | 2 | $40 |
| Noven Therapeutics, LLC | 1 | $23 |
| Neos Therapeutics, LP | 1 | $21 |
| Sun Pharmaceutical Industries Inc. | 1 | $20 |
| Tris Pharma Inc | 1 | $19 |
| Neuronetics, Inc. | 1 | $18 |
| Lilly USA, LLC | 1 | $14 |
| Bioxcel Therapeutics, Inc. | 1 | $14 |
How this compares
$10,688 in reported general payments places this provider in the 90th percentile of 1,838 psychiatry providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 20 | $205,631 |
| Austedo XrDeutetrabenazine | 14 | $181,045 |
| Invega TrinzaPaliperidone Palmitate | 27 | $172,176 |
| Invega SustennaPaliperidone Palmitate | 56 | $164,480 |
| UzedyRisperidone | 22 | $84,795 |
| Abilify MaintenaAripiprazole | 21 | $60,055 |
| RexultiBrexpiprazole | 32 | $47,955 |
| DayvigoLemborexant | 79 | $29,171 |
| NuedextaDextromethorphan Hbr/Quinidine | 21 | $27,237 |
| BelsomraSuvorexant | 51 | $23,991 |
| VraylarCariprazine Hcl | 13 | $21,352 |
| LybalviOlanzapine/Samidorphan Malate | 13 | $20,584 |
| RybelsusSemaglutide | 19 | $17,787 |
| Clozapine | 209 | $11,731 |
| TrintellixVortioxetine Hydrobromide | 26 | $11,680 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr, Uzedy | $2,586 | $471,47156 claims |
| Johnson & JohnsonInvega Trinza, Invega Sustenna | $543 | $336,65583 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $689 | $108,01053 claims |
| Eisai Inc.Dayvigo | $120 | $29,17179 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $44 | $27,23721 claims |
| MerckBelsomra | $535 | $23,99151 claims |
| AbbVieVraylar | $601 | $21,35213 claims |
| Alkermes, Inc.Lybalvi | $1,107 | $20,58413 claims |
| Novo NordiskRybelsus | $102 | $17,78719 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $395 | $11,68026 claims |
| Lilly USA, LLCOlanzapine | $14 | $4,300177 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,838 psychiatry providers in Pennsylvania.
Other psychiatry in Meadville
- Lee SpainMeadville$42K
- Cherian VergheseNorristown$16.3M
- Steven ArnoldPhiladelphia$4.1M
- Paul GrossAllentown$4.1M
- Shivkumar HattiMedia$4M
- Rebecca RomaPittsburgh$3.3M
- Matthew BergerMoosic$2.4M
- Michael ThasePhiladelphia$2.2M
- Robert NelsonWyomissing$2.2M
- Mark MattaNew Castle$847K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.